Atomwise Company

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at, or connect on Twitter and LinkedIn.
Technology: Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Medical, Pharmaceutical
Industry: Early Drug Development
Headquarters: San Francisco, California, United States
Founded Date: 2012-01-01
Employees Number: 101-250
Funding Status: Early Stage Venture
Investors Number: 22
Total Funding: 176645000
Estimated Revenue: $10M to $50M
Last Funding Date: 2020-10-06
Last Funding Type: Grant

Visit Website
Register and Claim Ownership